Camac

Camac Partners Calls on TuSimple to Take Long Overdue Step of Monetizing Remaining Assets and Returning Capital to Shareholders

Retrieved on: 
Thursday, May 30, 2024
Trucking, Professional Services, Transport, Finance, Camac, TuSimple, Partner, Management

Dear TuSimple Board of Directors,

Key Points: 
  • Dear TuSimple Board of Directors,
    We are a major independent shareholder of TuSimple, owning approximately 5.6% of the Company.
  • Despite this, TuSimple sat on net cash of more than $900 million as of last reported financials, which is a multiple of its market price.
  • The Board must act as a fiduciary to TuSimple’s shareholders and protect the Company’s assets for the benefit of all shareholders.
  • Trading 88% below the value of its excess cash, it is highly unlikely TuSimple can do anything remotely as sensible as returning excess capital to shareholders.

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom

Retrieved on: 
Wednesday, September 6, 2023
Professional Services, Finance, CARD, IPO, Drug development, Partner, Biotechnology, Stock dilution, Annual Meetings of the International Monetary Fund and the World Bank Group, Record, Atopic dermatitis, McIntyre, ANY, Annual general meeting, ATG, INFO, Camac, Private placement, Holding company, Private investigator, Management, Tobacco, Security (finance), Bank, Pharmaceutical industry, Vaccine, Shareholder, Forte, DRS

Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included in the Company’s recent presentation.

Key Points: 
  • Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included in the Company’s recent presentation.
  • Our Group has repeatedly made clear that there needs to be accountability in the boardroom and is not demanding liquidation.
  • Our independent director candidates – Messrs. Hacke and McIntyre – are open to exploring all options to improving Forte’s performance, strategy and governance.
  • VOTE “FOR” THE CONCERNED STOCKHOLDERS’ HIGHLY QUALIFIED NOMINEES ON THE WHITE PROXY CARD AHEAD OF FORTE’S ANNUAL MEETING ON SEPTEMBER 19, 2023.

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Retrieved on: 
Friday, August 25, 2023
Asset Management, Professional Services, Finance, Morgan Stanley, Partnership, PATH, Private, Barclays, Stock dilution, Clinical trial, NUALS Arts and Literary Annual Meet, INDEPENDENT, DRS, Macquarie Infrastructure Corporation, Atopic dermatitis, MS, MDR, Investment, Research fellow, McIntyre, Annual general meeting, Credit, Camac, Research, System, BCS, LP, WHO, NYSE, Security (finance), Management, Holding company, Cryptocurrency, Financial services, Forte

As of market close on May 24, 2023 (the day before Camac’s preliminary proxy statement was filed with the SEC).

Key Points: 
  • As of market close on May 24, 2023 (the day before Camac’s preliminary proxy statement was filed with the SEC).
  • Despite Forte peddling FB-102 as demonstrating potentially “best in class activity,” the reality is that the compound is still in preclinical indication.
  • Ahead of this year’s Annual Meeting, we want to ensure you have all the facts regarding this Board’s track record.
  • We look forward to being in touch in the coming weeks with more information about our highly qualified director candidates and their vision for Forte.

Pasithea Therapeutics to Call Special Meeting of Stockholders

Retrieved on: 
Monday, October 3, 2022
CNS, Lists of diseases, GLOBE, Concord, U.S. Securities and Exchange Commission, Amyotrophy, SEC, Nasdaq, Research, Psychopharmacology, McDermott Will & Emery, Camac, KTTA, Ketamine, LLC, ALS, Therapy, Special, MIAMI, Communication, Security (finance), Multiple sclerosis, Patient, Forward-looking statement, Central nervous system, Board of directors, Amyotrophic lateral sclerosis, Board, Company, Psychiatry, Pharmaceutical industry, Shareholder

Pasithea will call a Special Meeting in accordance with the Companys bylaws.

Key Points: 
  • Pasithea will call a Special Meeting in accordance with the Companys bylaws.
  • Additional details about the Special Meeting will be forthcoming.
  • Pasithea Therapeutics Corporation is a biotechnology company focused on the discovery, research and development of new and effective treatments for central nervous system (CNS) disorders.
  • Pasithea, its directors and certain of its executive officers and employees are deemed to be participants in a solicitation of requests not to vote for the Camac Groups proposal at the Special Meeting (the Special Meeting Solicitation).

Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise

Retrieved on: 
Wednesday, August 17, 2022
Asset Management, Professional Services, Finance, Company, Investment, Board, Hand, Schedule 13D, LLC, Nasdaq, Partner, Nature, Security (finance), Camac, Forte

Eric Shahinian, founder and managing member of Camac, commented:

Key Points: 
  • Eric Shahinian, founder and managing member of Camac, commented:
    Since Fortes initial public offering, the Companys share price has declined approximately 95%.
  • We believe shareholders have lost all confidence in Forte due to the Board and managements failure to establish a sensible capital allocation strategy, as well as inexcusable lapses in governance.
  • We understand why the Company now trades at an approximately 40% percent discount to its roughly $45 million in cash.
  • Its investments are long term in nature and focused on compounding capital over several decades rather than months or years.

Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Group’s Unjustified Campaign

Retrieved on: 
Tuesday, August 2, 2022
Running, Acquisition, Time, IPO, Date, Lists of diseases, Multiple sclerosis, GLOBE, KTTA, Biogen, U.S. Securities and Exchange Commission, Johnson & Johnson, Amyotrophic lateral sclerosis, Psychiatry, Schizophrenia, Crohn's disease, Camac, Annual general meeting, Research, GOLD, Board, Therapy, Biotechnology, CEO, FOR, Integrin, Director, MS, ALS, Company, Patient, Nasdaq, LLC, Bring Your Board!!, Letter, Concord, Neurocrine Biosciences, Pharmaceutical industry, Holding company, Fine chemical, Shareholder, Janssen Biotech, Natalizumab

MIAMI BEACH, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of new and effective treatments for psychiatric and neurological disorders, today announced that it has filed its definitive consent revocation statement with the U.S. Securities and Exchange Commission (“SEC”) and sent a letter to Pasithea stockholders. The letter outlines Pasithea’s response to the consent solicitation to call a Special Meeting of Stockholders (“Special Meeting”) by Camac Partners, LLC, Camac Capital, LLC, Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Eric Shahinian, David Delaney, and Avi Geller (collectively, the “Camac Group”). The Board of Directors of Pasithea unanimously urges stockholders to reject what it believes is the Camac Group’s misguided and self-serving attempt to undermine the Company’s progress and destroy its meaningful upside potential. Pasithea urges its stockholders to sign, date, and return Pasithea’s GOLD consent revocation card and discard any white consent solicitation card received from the Camac Group.

Key Points: 
  • The Board of Directors of Pasithea unanimously urges stockholders to reject what it believes is the Camac Groups misguided and self-serving attempt to undermine the Companys progress and destroy its meaningful upside potential.
  • Pasithea urges its stockholders to sign, date, and return Pasitheas GOLD consent revocation card and discard any white consent solicitation card received from the Camac Group.
  • The letter to stockholders outlines the Companys commitment to advancing its potentially groundbreaking therapies to grow stockholder value and underscores how Pasithea believes the Camac Groups self-serving and short-sighted campaign is an attempt to co-opt the Companys cash and eliminate significant potential future value from stockholders.
  • YOU INVESTED IN AN EARLY-STAGE BIOTECH, PASITHEA, FOR ITS SIGNIFICANT POTENTIAL UPSIDE
    Your Board unanimously urges you to reject the Camac Groups short-sighted campaign by signing, dating and returning the GOLD consent revocation card and discarding any further materials and white consent cards you receive from the Camac Group.

GA Telesis Flight Solutions Group Receives Chinese CAMAC Certificate of Civil Aircraft Parts Distributor

Retrieved on: 
Wednesday, March 24, 2021
Air, Transport, Aerospace, Manufacturing, Articles, Architectural theory, Ontology, Telesis, Urbanization, Camac, Civil Aviation Administration of China, Academic disciplines

GA Telesis, LLC (GAT) announces it has been granted a Certificate of Civil Aircraft Parts Distributor from the Civil Aviation Maintenance Association of China (CAMAC).

Key Points: 
  • GA Telesis, LLC (GAT) announces it has been granted a Certificate of Civil Aircraft Parts Distributor from the Civil Aviation Maintenance Association of China (CAMAC).
  • This marks GA Telesis as the first foreign entity to receive the highly coveted CAMAC certification, allowing GAT to sell and lease civil aviation parts, both new and used, in China.
  • This certificate's award is a testament to the strong, long-term relationship GA Telesis Flight Solutions Group (FSG) has built with Chinese customers, CAMAC, and the Civil Aviation Administration of China, the CAAC.
  • Through the GA Telesis Ecosystem, the Company is distinctly positioned, across six continents, to leverage its resources to create innovative solutions for its customers.

Camac Nominates Seven Highly Qualified Director Candidates for Election at Cedar Realty Trust's 2021 Annual Meeting

Retrieved on: 
Monday, March 1, 2021
Camac, Cedar Realty Trust

NEW YORK, March 1, 2021 /PRNewswire/ --Camac Partners, LLC ("Camac") today announced that its affiliate has nominated a slate of seven highly qualified director candidates for election to the board of directors of Cedar Realty Trust, Inc. (NYSE: CDR) ("Cedar Realty").

Key Points: 
  • NEW YORK, March 1, 2021 /PRNewswire/ --Camac Partners, LLC ("Camac") today announced that its affiliate has nominated a slate of seven highly qualified director candidates for election to the board of directors of Cedar Realty Trust, Inc. (NYSE: CDR) ("Cedar Realty").
  • If elected, Camac's nominees would replace directors who have overseen the decline of almost $500 million of value at Cedar Realty.
  • Camac has received significant positive feedback since the release of its plan to unlock value at Cedar Realty.
  • This feedback validates Camac's views that meaningful and immediate change is needed at Cedar Realty.

Camac Reports Successful Certification of Votes for Call of Special Meeting

Retrieved on: 
Friday, August 23, 2019
Banking, Professional services, Finance, SEC filings, Camac, Proxy

Camac Partners, LLC (Camac), the investment manager of Camac Fund, LP, today announced that it was successful in its efforts to request the call of a special meeting of stockholders of Liberated Syndication, Inc. (OTCQB: LSYN) (Libsyn).

Key Points: 
  • Camac Partners, LLC (Camac), the investment manager of Camac Fund, LP, today announced that it was successful in its efforts to request the call of a special meeting of stockholders of Liberated Syndication, Inc. (OTCQB: LSYN) (Libsyn).
  • If Libsyn does not call a special meeting, then Camac is permitted to call the special meeting beginning on September 14, 2019.
  • On August 8, 2019, Camac filed a preliminary proxy statement in connection with the special meeting of stockholders of Libsyn.
  • Prior to the special meeting of stockholders, Camac intends to furnish a definitive proxy statement, together with a WHITE proxy card, to Libsyns stockholders.

Camac Partners Successful in Request to Call Special Meeting of Stockholders of Liberated Syndication

Retrieved on: 
Tuesday, July 16, 2019
Banking, Professional services, Finance, Camac

Camac Partners, LLC (Camac), the investment manager of Camac Fund, LP, today announced that it has received sufficient support from its fellow stockholders to request the call of a special meeting of stockholders of Liberated Syndication, Inc. (OTCQB: LSYN) (Libsyn).

Key Points: 
  • Camac Partners, LLC (Camac), the investment manager of Camac Fund, LP, today announced that it has received sufficient support from its fellow stockholders to request the call of a special meeting of stockholders of Liberated Syndication, Inc. (OTCQB: LSYN) (Libsyn).
  • If Libsyn does not take appropriate action to call a special meeting, then Camac is permitted to call the special meeting.
  • Camac, together with the other participants identified below, has requested the call of a special meeting of stockholders of Libsyn.
  • Camac, Camac Capital, LLC, Camac Fund, LP, Eric Shahinian, Michael Cricenti, Simeon McMillan, Adam Pincus and Bradley M. Tirpak are participants in the solicitation of special meeting requests from stockholders of Libsyn.